Touchlight, founded in 2007 and headquartered in Hampton, London, is a biotechnology company specializing in the enzymatic production of synthetic DNA through its proprietary "doggybone" DNA (dbDNA) technology. This platform enables rapid, scalable, and high-purity DNA manufacturing, serving applications across genetic medicine, including mRNA vaccines, gene therapies, and genome editing. In 2023, Touchlight completed the expansion of its GMP-certified manufacturing facility, tripling its production capacity to over 8 kg of DNA annually, surpassing the current global supply of plasmid DNA. The company's dbDNA technology has been adopted by leading biopharmaceutical companies, including a licensing agreement with GSK for the development and production of mRNA-based products.